, Volume 64, Issue 2, pp 171–179 | Cite as

A rating scale for tardive dyskinesia

  • G. M. Simpson
  • J. H. Lee
  • B. Zoubok
  • G. Gardos
Original Investigations


A rating scale for tardive dyskinesia was developed, consisting of nearly all signs seen by two groups of investigators over a 5-year period. Thirty-four items were included in the scale with a possibility of writing in idiosyncratic signs. The scale was shown to have good reliability and validity in studies carried out by both the New York and Boston groups. It is recommended as a suitable instrument for describing the breadth of tardive dyskinesia syndrome and also for quantifying the disorder. A second scale, “the abbreviated dyskinesia scale”, contains 13 items which are more global than the items in the original scale. It also has been shown to be both reliable and valid. Its use is suited to situations requiring less extensively detailed assessments.

Key words

Dyskinesia Rating scale Clinical trials 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cole, J. O., Gardos, G., Tarsy, D., et al.; Drug trials in persistent dyskinesia, in press (1979)Google Scholar
  2. Crane, G. E., Paulson, G.: Involuntary movements in a sample of chronic mental patients and their relation to the treatment with neuroleptics. Int. J. Neuropsychiatry 3, 286–291 (1967)Google Scholar
  3. Faurbye, A., Rasch, P. J., Petersen, P. B., Brandborg, G., Pakkenberg, H.: Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr. Scand. 40, 1027 (1964)Google Scholar
  4. Gardos, G., Cole, J. O., Sniffin, C.: An evaluation of papaverine in tardive dyskinesia. J. Clin. Pharmacol. 16, 5–6 (1976)Google Scholar
  5. Gardos, G., Sokol, M., Cole, J. O., Sniffin, C.: Eye color and tardive dyskinesia. Psychopharmacol. Bull. 2, 7–9 (1976b)Google Scholar
  6. Gardos, G., Cole, J. O., LaBrie, R. A.: The assessment of tardive dyskinesia. Arch. Gen. Psychiatry 34, 1206–1212 (1977)Google Scholar
  7. National Institute of Mental Health, Psychopharmacology Research Branch: Development of a dyskinetic movement scale. ECDEU Intercom. 4, 3–6 (1975)Google Scholar
  8. Sigwald, J., Bouttier, D., Courvoisier, S.: Les accidents neurologiques des medications Neuroleptiques. Rev. Neurol. (Paris) 100, 553–595 (1959a)Google Scholar
  9. Sigwald, J., Bouttier, D., Raymondeaud, C., Piot, C.: Quatre cas de dyskinesie facio-bucco-linguomasticatrice a evolution prolongee secondaire a un traitement par les neuroleptiques. Rev. Neurol. (Paris) 100, 751–755 (1959b)Google Scholar
  10. Simpson, G. M., Angus, J. W. S.: A Rating Scale for Extrapyramidal Side Effects. Acta Psychiatr. Scand. (Suppl.) 212, 1970Google Scholar
  11. Simpson, G. M., Branchey, M. H., Lee, J. H., Voitashevsky, A., Zoubok, B.: Lithium in tardive dyskinesia. Pharmakopsychiatr. Neuropsychopharmakol. 9, 76–80 (1976a)Google Scholar
  12. Simpson, G. M., Shrivastava, R., Lee, J. H.: Clozapine in tardive dyskinesia. Psychopharmacology 56, 75–80 (1978)Google Scholar
  13. Simpson, G. M., Voitashevsky, A., Young, M. A., Lee, J. H.: Deanol in the treatment of tardive dyskinesia. Psychopharmacology 52, 257–261 (1977)Google Scholar
  14. Simpson, G. M., Zoubok, B., Lee, J. H.: An early clinical and toxicity trial of EX 11-582A in chronic schizophrenia. Curr. Ther. Res. 1, (1976b)Google Scholar
  15. Schonecker, M.: Ein eigentümliches Syndrom im oralen Bereich bei Megaphen Applikation. Nervenarzt 28, 35 (1957)Google Scholar
  16. Uhrbrand, L., Faurbye, A.: Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia (Berl.) 1, 408–418 (1960)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • G. M. Simpson
    • 3
  • J. H. Lee
    • 1
  • B. Zoubok
    • 1
  • G. Gardos
    • 2
  1. 1.Rockland Research InstituteOrangeburgUSA
  2. 2.Boston State HospitalBostonUSA
  3. 3.USC-MSH Psychopharmacological ServicesNorwalkUSA`

Personalised recommendations